Clinical Trial

Efficacy and Safety of Dapagliflozin in Children With Proteinuria

Active, Not Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated October 2, 2025 (before its estimated June 2026 completion). Its status may not reflect the trial's current state.
Summary
This interventional study investigates the efficacy of dapagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, in pediatric patients with renal disease. The primary outcomes include changes in 24-hour proteinuria indexed to body surface area (mg/m²/day) and glomerular filtration rate (GFR) before and after dapagliflozin administration. By closely monitoring these parameters, the study aims to assess the renal protective potential of dapagliflozin in children and adolescents.
Trial Details
NCT Number NCT07204743
Lead Sponsor Al-Quds University
Conditions SGLT 2 Inhibitors, Pediatric Kidney Disease, Proteinuric Diseases, Dapagliflozin (Forxiga)
Enrollment 10 participants
Start Date 2025-08-15
Primary Completion 2026-06 (estimated)
Study Completion 2026-08 (estimated)
Updated on ClinicalTrials.gov 2025-10-02